| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.08▲ | 1.09▲ | 1.09▲ | 1.10▲ | 1.15▼ |
| MA10 | 1.08▲ | 1.09▲ | 1.08▲ | 1.15▼ | 1.24▼ |
| MA20 | 1.08▲ | 1.08▲ | 1.11▼ | 1.15▼ | 1.35▼ |
| MA50 | 1.08▲ | 1.15▼ | 1.16▼ | 1.27▼ | 1.21▼ |
| MA100 | 1.12▼ | 1.17▼ | 1.17▼ | 1.37▼ | 1.12▼ |
| MA200 | 1.16▼ | 1.16▼ | 1.20▼ | 1.22▼ | 3.47▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.005▲ | 0.002▲ | -0.002▼ | -0.050▼ |
| RSI | 62.439▲ | 47.709▼ | 43.732▼ | 40.767▼ | 43.426▼ |
| STOCH | 27.778 | 48.485 | 61.439 | 24.134 | 17.905▼ |
| WILL %R | 0.000▲ | -9.091▲ | -33.333 | -70.833 | -91.855▼ |
| CCI | 214.135▲ | 109.854▲ | 72.142 | -96.626 | -92.543 |
|
Tuesday, September 16, 2025 05:14 AM
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a ...
|
|
Wednesday, September 10, 2025 05:29 AM
NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to ...
|
|
Tuesday, July 29, 2025 04:58 AM
The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries "We are delighted with the addition of clinical sites in the EU and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/12/25 | 1.10 | 1.10 | 1.10 | 1.10 | 32,342 |
| 17/12/25 | 1.06 | 1.11 | 1.06 | 1.07 | 87,800 |
| 16/12/25 | 1.10 | 1.10 | 1.03 | 1.05 | 249,300 |
| 15/12/25 | 1.17 | 1.17 | 1.09 | 1.09 | 154,900 |
| 12/12/25 | 1.20 | 1.22 | 1.16 | 1.17 | 70,828 |
| 11/12/25 | 1.20 | 1.23 | 1.17 | 1.21 | 87,500 |
| 10/12/25 | 1.20 | 1.25 | 1.18 | 1.21 | 164,100 |
| 09/12/25 | 1.18 | 1.195 | 1.17 | 1.19 | 85,200 |
| 08/12/25 | 1.20 | 1.20 | 1.16 | 1.16 | 115,900 |
| 05/12/25 | 1.17 | 1.22 | 1.17 | 1.20 | 115,100 |
|
|
||||
|
|
||||
|
|